German pharmaceutical giant Bayer, which is facing a legal bid by generic drug maker Sandoz to invalidate patents covering blood clot drug Xarelto, is seeking to amend one of the patents in dispute.
The Full Federal Court has rejected German drug maker Boehringer Ingelheim’s appeal of ruling that shot down its opposition to Merck Sharp & Dohme’s patent application for an injectable anti-parasite drug for livestock.
The High Court has been asked to wade into the debate over whether artificial intelligence can be named as an inventor on patent applications, after the Full Court overturned a landmark victory for AI pioneer Dr Stephen Thaler.
The Full Court has overturned a landmark judgment which found artificial intelligence can be named as an inventor on patent applications, in a decision which brings Australia in line with findings from courts in the UK, US and EU.
The ACCC has refused to authorise a patent settlement and license agreement between Bristol-Myers Squibb unit Celgene and two generic drug makers who sued to invalidate the patents for its blockbuster cancer drug Revlimid, saying it could distort competition between generic drug makers.
The Full Court has upheld two judgments that shortened patent term extensions granted to Merck Sharpe & Dohme and Ono Pharmaceuticals, finding the extension regime cannot be construed as achieving a “commercial outcome for a patentee”.
The High Court has found that Novartis unit Sandoz infringed Danish drug company Lundbeck’s patent for its blockbuster antidepressant Lexapro, but has overturned a ruling that found the generic drug maker owes $26.3 million in damages.
A toy designer that has been sued for allegedly copying the design of toy maker Jellycat’s beloved ‘Bashful Bunny’ has pushed back at a request for discovery concerning its design process, telling the court “a plush toy in the shape of a bunny is hardly a revolutionary concept”.
Bristol-Myers Squibb unit Celgene has dropped a lawsuit accusing Indian generics company Dr Reddy’s Laboraties of threatening to infringe its patent for Revlimid with the planned launch of a generic version of the blockbuster cancer drug in Australia.
Tech company Vehicle Management Systems has come up short in its third attempt to block competitor SARB Management Group’s patent application for a magnetic parking overstay detector, with the Full Court rejecting claims that VMS’ managing director should have been listed as the device’s inventor.